The HIV PCP is a CME/CE multi-module educational certification program that will prepare providers to utilize the most individualized and up-to-date methods to prevent HIV infection.  Upon completion of the self-paced program, providers will earn a HIVPCP certificate. The HIVPCP certification demonstrates competency in interdisciplinary, multi-level strategies for HIV prevention. 

Participants who complete the certification program will have an understanding of the foundation of HIV epidemiology and policy in the United States, the provider’s role in identifying HIV risk and new cases, high impact strategies to prevent HIV through status-neutral-navigation, clinical guidelines to implement PrEP, and a framework of cultural humility that improves clients’ access to and retention in care.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists,  internists, primary care physicians, nurses, pharmacists, and other clinicians involved in the care of  patients at risk of acquiring or transmitting HIV. 

  • Media: Enduring Material 

  • Original Release date for Modules 1-5: October 16, 2019

  • Original Release date for Modules 6: July 12, 2021

  • Release date for Modules 1-5, 7, and 8: March 21, 2022 

  • Expiration dates for Modules 1-8: March 20, 2023

  • Time to Complete Modules 1-5, 7, and 8: 60 minutes

  • Time to Complete Module 6: 90 minutes

Accreditation, Credit, and Support
PeerView Institute LogoRound MLI logoHealthHIV logo
Modules 1-5, 7, & 8
Joint accreditation logoIn support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., HealthHIV, and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
 Modules 1-5, 7, & 8 are supported by an educational grant from Gilead Sciences, Inc.

Module 6
Jointly provided by Postgraduate Institute for Medicine and HealthHIV.
Module 6 was supported by an educational grant from OraSure/UrSure, Inc.
Physician Continuing Medical Education
Modules 1-5, 7, & 8
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 6
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Modules 1-5, 7, & 8Logo for CME MOC Accreditation
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Module 6
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Nursing Continuing Professional Development
Modules 1-5, 7, & 8
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Module 6
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Continuing Pharmacy Education
Modules 1-5, 7, & 8
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number:
  • Mod 1: JA0007322-9999-21-055-H01-P
  • Mod 2: JA0007322-9999-21-056-H01-P
  • Mod 3: JA0007322-9999-21-057-H01-P
  • Mod 4: JA0007322-9999-21-058-H01-P
  • Mod 5: JA0007322-9999-21-059-H01-P
  • Mod 7: JA0007322-9999-21-060-H01-P
  • Mod 8: JA0007322-9999-21-061-H01-P
Type of Activity: Knowledge

Module 6
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2859-H01-P
Type of Activity: Application
Planning Committee and Content/Peer Reviewers The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, PVI, PeerView Institute for Medical Education, and HealthHIV, our educational partners, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

Welcome to HIV PCP! To enroll in all the courses in the program click Enroll in all Courses. To enroll in a specific course click on the course title to open the course then click enroll. 

Course Description This module focuses on the history and epidemiology of HIV in the US, current HIV policies, strategies for prevention and invention, and the role of HIV prevention certification.

Faculty: Jonathan Appelbaum MD FACP AAHIVS

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Explain the history and epidemiology of HIV in the United States

  • Describe current policies regarding treatment for and prevention of HIV/AIDS

  • Identify strategies for HIV prevention and intervention

  • Discuss the economics of HIV

  • Describe the role of the HIV Prevention certification

Universal Activity Number: JA0007322-9999-21-055-H01-P 

Original Release Date: October 16, 2019
New Release Date: March 21, 2022
Expiration Date: March 20, 2023


Course Description This module focuses on the screening and diagnosis of HIV, identifying HIV risk, behavioral interventions, and leveraging partnerships.

Faculty: Jonathan Appelbaum MD FACP AAHIVS

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Describe screening for and diagnosis of HIV Infection

  • Explain how to identify HIV risk

  • Identify appropriate short behavioral interventions

  • Describe the importance of leveraging clinic and community partners

Universal Activity Number: JA0007322-9999-21-056-H01-P 

Original Release Date: October 16, 2019
New Release Date: March 21, 2022
Expiration Date: March 20, 2023


Course Description This module focuses on preventing HIV through PEP and PrEP, STI screening, and U=U in HIV care.

Faculty & Narration: Jonathan Appelbaum MD FACP AAHIVS & Alan McCord

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Explain how to prevent HIV through post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP)

  • Describe the importance of sexually transmitted infection screening and treatment for HIV prevention

  • Describe the meaning of U=U and implications for HIV care

Universal Activity Number: JA0007322-9999-21-057-H01-P 

Original Release Date: October 16, 2019
New Release Date: March 21, 2022
Expiration Date: March 20, 2023


Course Description This module focuses on pre-exposure prophylaxis inventions, research to support efficacy, the current guidance from the CDC, along with emerging modalities.

Faculty & Narration: Richard Elion MD & Brian R. Wood MD
Contributors: Alan McCord & TJ Moore MPH

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Describe the clinical basics of a pre-exposure prophylaxis intervention, including medication, adherence, and effectiveness.

  • Explain research findings supporting PrEP efficacy.

  • Discuss the Center for Disease Control and Prevention’s PrEP guidance including risk assessment, testing, PrEP prescription, PrEP coverage, and follow-up.

  • Describe emerging modalities for PrEP.

Universal Activity Number: JA0007322-9999-21-058-H01-P 

Original Release Date: October 16, 2019
New Release Date: March 21, 2022
Expiration Date: March 20, 2023


Course Description This module focuses on the role that stigma, discrimination, trauma and social determinants of health play in HIV prevention and care and ways mitigate their impact through cultural humility and trauma-informed care.

Faculty: Christopher Hucks-Ortiz, MPH

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Describe the integrated continuum of HIV prevention and treatment
  • Discuss the role of intersectional stigma (ie. race, sex, gender, orientation, HIV status), discrimination, trauma, and social determinants of health in HIV risk
  • Explain cultural humility and the role it plays in providing HIV care and overcoming barriers to care
  • Describe trauma-informed care and its importance in HIV treatment and prevention
  • Introduce resources to mitigate financial barriers for clients

Universal Activity Number: JA0007322-9999-21-059-H01-P 

Original Release Date: October 16, 2019
New Release Date: March 21, 2022
Expiration Date: March 20, 2023


Course Description This module focuses on National PrEP guidelines, adherence monitoring, challenges around implementing PrEP, and strategies that support PrEP users.

Faculty: Brandon Wilson, DrPH, MHA, Omar Martinez, JD, MPH, MS, Michael Kharfen

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Demonstrate knowledge and competency of National PrEP guidelines.

  • Identify the strengths and limitations of objective adherence monitoring.

  • Name typical challenges that providers may face when implementing PrEP, and strategies for reducing those challenges.

  • Provide adherence education, monitoring, and support to PrEP candidates and users.

Universal Activity Number: JA4008162-9999-21-2859-H01-P 

Original Release and Expiration Dates: July 12, 2021–March 20, 2023


Course Description This module focuses on strategies to address barriers to PrEP access among underserved and under-resourced populations and future innovations for PrEP care.

Faculty: Mauda Monger PhD MPH, K Rivet Amico PhD, & Tamara Taggart PhD MPH

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Identify populations vulnerable to HIV infection who also experience disparities around PrEP.

  • Describe how the social determinants of health and barriers to healthcare impact PrEP uptake.

  • Identify trends in PrEP use and persistence among different populations.

  • Describe different navigation models that can improve access to PrEP.

  • Identify strategies that providers can use to support PrEP adherence among vulnerable populations.

Universal Activity Number: JA0007322-9999-21-060-H01-P 

Release Date: March 21, 2022
Expiration Date: March 20, 2023


Course Description This module focuses on the benefits and application of TelePrEP services and models for delivery and implementation.

Faculty: Rupa Rajesh Patel MD MPH DTM&H

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Identify the benefits of using TelePrEP for HIV prevention

  • List the various components of a TelePrEP program

  • Summarize the role of TelePrEP peer navigators

  • Identify three (3) commercial or state-run TelePrEP service providers

  • Describe possible challenges that TelePrEP service delivery may cause for clients, providers, or organizations

Universal Activity Number: JA0007322-9999-21-061-H01-P 

Release Date: March 21, 2022
Expiration Date: March 20, 2023


Final Certificate awarded after completion of all eight HIV PCP modules. Once complete register for the national database and receive your certificate.